Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Chicago
Regeneron Pharmaceuticals
Genmab
Genmab
Genmab
Allogene Therapeutics
Fred Hutchinson Cancer Center
Lyell Immunopharma, Inc.
Novartis
Essen Biotech